The omega-3 index: how to read your number and what actually raises it

The searches that bring people to this topic are very concrete: "what is my DHA level", "what do EPA and DHA levels mean", "omega-3 index normal range". In other words, the person is already holding a lab report with a number on it and wants to know what to do with it. Why the marker exists at all we cover separately — the omega-3 index and longevity. This piece is about something else: how the number is actually built, why two laboratories can disagree about the same person, what genuinely moves it — and where the evidence stops.

What is actually measured — and why "omega-3 in blood" is not one test

In its original definition, the omega-3 index is the sum of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in red blood cell membranes, expressed as a percentage of all fatty acids in that membrane. Harris and von Schacky proposed it in 2004 as a standard metric with a described method: a sample preparation, chromatography and proposed cut-offs. The caveat matters: the 2004 paper described a method and proposed boundaries, while the strict protocol with inter-laboratory comparisons and external quality control came later.

The key word is erythrocyte. A red cell membrane lives as long as the cell does, and a red cell survives on the order of one hundred and twenty days, so its fatty acid composition averages intake over months. That is what separates the index from "omega-3 in plasma" or "in serum": those measure what is circulating right now, and are influenced by what the person ate yesterday.

So the first question to ask of a report is not "how much" but what exactly was counted:

• red blood cells — the index in its original sense, a long-term characteristic;

• whole blood — a related quantity, but not the same one; published equations exist to convert it to a red-cell equivalent, and without that conversion the numbers are simply different;

• plasma or serum (total lipids, phospholipids, cholesteryl esters) — a short-term picture, sensitive to the last meal;

• "omega-3 index" with no matrix stated — the most common option on commercial panels and the least useful for comparison with anything.

The second question is what went into the sum. The classical index is EPA + DHA, and nothing else. Panels frequently print alpha-linolenic acid (ALA), docosapentaenoic acid (DPA), an omega-6/omega-3 ratio or an AA/EPA ratio alongside it. Those are different quantities with different ranges, and they cannot be dropped into a conversation about "the 8% target".

Numbers from different laboratories do not compare

This is the practical core of the article, and it is usually not printed on the report.

Fatty acid analysis is not a routine chemistry test with inter-laboratory standardisation the way glucose is. The result depends on how the sample was drawn, stored and shipped, how the lipids were extracted, how the fatty acids were converted to volatile derivatives, and against which standard the peak areas were quantified. A standardised protocol has good analytical reproducibility, but that reproducibility belongs to that protocol, not to the genre of test.

Hence the rule everything else follows from: a trend is only meaningful within one laboratory and one method. A second measurement taken somewhere else answers a different question, and the difference between the first and second number may be a difference between methods rather than a change in the person.

The same applies to a fingerstick dried blood spot sample: it is convenient and validated versions of it exist, but what is validated is a specific protocol — a specific card, specific drying conditions, a specific shipping time and temperature. "A finger-prick test" as a genre guarantees nothing.

Where the "below 4%" and "above 8%" zones come from

The division into low (roughly below 4%), intermediate (4–8%) and high (above 8%) was proposed by the authors of the index and rests on cardiology work comparing blood omega-3 content in people who died suddenly of cardiac causes and people who did not. In other words, these are proposed risk zones for one specific outcome, not a reference interval derived from observing lifespan, and not a "normal range" in the laboratory sense.

It is worth looking at what they were assembled from, because even the quantity measured differs between those studies. A prospective case-control study in men with no prior cardiovascular disease (94 cases of sudden death as the first manifestation against 184 controls) measured long-chain omega-3s in whole blood, not the red-cell index. A population-based study of primary cardiac arrest (334 cases, aged 25–74) measured total omega-3s in the red cell membrane, not strictly the sum of EPA and DHA as defined in 2004. The third source was a secondary-prevention trial in post-infarction patients, where the index was not measured at all — it was estimated from the dose used. The authors of the index mapped all of this onto one scale: the 4% and 8% boundaries are therefore the product of transfer, which is worth remembering when reading them as something precise.

The distinction matters more than it seems. A laboratory reference range is normally built as the spread of values in healthy people. The index zones were built the other way round: from an outcome back to the marker. So a number below four per cent is correctly read as "little omega-3 in membranes compared with populations in which this outcome is less frequent", not as a diagnosis or a deficiency in the clinical sense.

Second, the underlying studies were run between the late 1980s and the mid-1990s — that is, before statins were in widespread use. Nor is there a single population behind the boundaries: two of the key studies were done in people without established cardiovascular disease, while the third source was, conversely, secondary prevention after myocardial infarction. Applying these boundaries to someone who already has a diagnosis and takes a statin and other drugs is extrapolation, not the reading of a reference range.

What the numbers look like across populations

A global survey of EPA and DHA in the blood of healthy adults found a very wide spread between regions: high values where oily marine fish is eaten regularly and in quantity (Japan, Scandinavia, coastal indigenous populations), low values across North America, much of Europe, Southeast Asia and inland regions generally.

One practical and somewhat unexpected conclusion follows: "below average for your country" and "low by the index zones" are different statements, and in most countries the population average sits entirely within the intermediate or low zone. Comparing yourself with your regional average does not answer the question of whether your value is high or low.

What moves the number: dose, time, and a very large between-person spread

The index responds to EPA and DHA intake in a dose-dependent way: the more arrives from food or supplements, the higher their share in the membrane. This has been shown in randomised trials with different doses and with the index itself measured as an endpoint.

What popular articles usually leave out starts here.

Time. The membrane changes as the cell pool turns over, so a new steady state is reached over months, not weeks. In a controlled study with a year of intake followed by withdrawal, the half-time for EPA incorporation into the red cell membrane was about four weeks and the plateau was approached closer to six months; three to four months is enough to come very near the new level. A measurement two weeks after starting shows a transitional state, not a result. The same holds in reverse: the index does not collapse the moment intake stops — in that same study roughly half of the gained EPA was lost over four weeks after withdrawal, and DHA returns to baseline more slowly still.

Between-person spread. At an identical dose the increase differs several-fold between people: in a randomised trial of 115 healthy adults aged 20–45 across five doses, the gain on the highest dose ranged from roughly three to seven percentage points. The most consistent predictors of response are dose relative to body weight (at a greater body mass the same milligram is distributed through a larger volume) and the starting level — the lower the baseline, the larger the visible gain. Age, sex and physical activity enter the model as weaker but reproducible contributors. Genotype was not measured in that trial at all — so the popular explanation "my genes are why it does not move" was simply never tested there. This is exactly why "how much do I need to reach 8%" has no single answer for everyone, and why any specific answer to it is a prescription rather than a fact.

What does not move the number much. One-off "loading" doses, a two-week course "for prevention", and supplements in which EPA and DHA are present in trace amounts for the sake of the front label. What counts is not capsules or millilitres of oil but the grams of EPA and DHA themselves — on a label those are two separate figures, and the second is almost always the smaller one.

Form, food, and plant sources

Form affects absorption. Fish oil is sold as natural triglycerides, re-esterified triglycerides, ethyl esters and free fatty acids, and as phospholipids (krill). Bioavailability studies show absorption differs between forms; ethyl esters are particularly sensitive to whether they are taken with a fat-containing meal.

Food alongside the capsule is not a detail — but not equally for every form. It matters most for ethyl esters: in pharmacokinetic studies their absorption on an empty stomach or a low-fat meal was several times lower than with a fat-containing meal. For natural triglycerides and free fatty acids the dependence on dietary fat is markedly weaker. So "I take it and the index does not move" is first of all a question about which form the product is and what it is taken with.

Plant sources are a separate story. Flaxseed oil, chia and walnuts supply ALA — also an omega-3, but neither EPA nor DHA. The body can convert ALA to EPA and onward to DHA, but the efficiency of that pathway in humans is low and — importantly — depends on sex. In stable-isotope studies, young healthy men converted on the order of eight per cent of the labelled ALA to EPA, with no detectable conversion to DHA; in young women the same estimates were considerably higher, around twenty-one per cent to EPA and about nine per cent to DHA. These are estimates of tracer distribution in plasma lipids in small samples, not a statement of how many spoons of flaxseed oil replace fish. So ALA is not an equivalent of fish for this particular marker. Algal DHA and EPA preparations are a separate case: they are a direct source of the same acids rather than a route through conversion.

Oily marine fish remains the densest dietary source, but EPA and DHA content varies considerably between species and even within a species, depending on whether the fish was wild or farmed and on what it was fed. There is no universal "so many grams of fish equals so many per cent".

🔴 Everything above describes how the marker behaves; none of it is a recommended regimen. Dose, form and whether to supplement at all are matters for a conversation with a doctor — particularly if you take medication affecting coagulation or are preparing for surgery. For accuracy: a pooled analysis of randomised trials did not show a clinically meaningful increase in bleeding at ordinary doses, and with a high dose of purified EPA the absolute increase was small. That is not a reason to ignore the question — it is a reason to put it to a doctor rather than answer it yourself in either direction.

What the number does not tell you

This is the line most often crossed in this niche.

The link with outcomes comes from observation. A pooled analysis of individual data from seventeen prospective cohorts — 42,466 participants, mean age at baseline around sixty-five, median follow-up sixteen years — found all-cause mortality roughly fifteen to eighteen per cent lower in the top quintile of circulating long-chain omega-3s than in the bottom one. Two caveats are obligatory. First, what was measured there was not a single index: across cohorts it was red-cell phospholipids, plasma phospholipids, cholesteryl esters and whole plasma — "blood levels", not one and the same quantity. Second, this is cohort observation, and people with high levels differ from people with low ones in far more than the level: diet, income, smoking and a dozen other things.

Supplement trials produced a mixed picture, and the mixture is explicable. A large primary-prevention trial in almost twenty-six thousand people at roughly one gram a day showed no significant advantage on either of its two primary endpoints — neither major cardiovascular events nor invasive cancer; there was a separate signal on a secondary endpoint for myocardial infarction, but secondary findings need confirmation rather than promotion into the conclusion.

A trial of a high dose of a purified EPA ethyl ester — four grams a day — in high-risk patients with elevated triglycerides on statins did show a reduction in events. That is a different population, a different dose and one acid instead of two; on top of which the comparator was mineral oil, LDL cholesterol and C-reactive protein rose in the placebo arm, and the neutrality of such a placebo is still disputed.

A third trial — a high dose of an EPA plus DHA mixture in a close but not identical population (high risk, high triglycerides, statins, but additionally requiring low HDL) and against a different comparator, corn oil — was stopped early for futility. Reducing all of this to "omega-3 works" or "omega-3 does not work" is equally wrong: whether it works is always the question "in whom, at what dose, in what form, against which placebo, for which outcome".

High doses carry a signal for atrial fibrillation. In a meta-analysis of seven randomised cardiovascular outcome trials (over eighty thousand participants), omega-3 supplementation was accompanied by an increased rate of newly detected atrial fibrillation, and the rate was appreciably higher in trials testing more than one gram a day than in those testing up to one gram. An important qualification: that is a comparison between trials, not an individual dose-response curve in one person. It is not an argument against measuring the index — it is an argument against prescribing yourself a high dose to chase a target figure.

The index appears in none of the common composite biological-age scores — not in PhenoAge, not in standard implementations of the Klemera–Doubal method. We have separate pieces on how biological age is calculated and on what the gap between biological and chronological age means. The omega-3 index lives beside them as a marker in its own right, not as one of their components.

What is missing from the field

There is no completed trial in which the intervention targeted the index itself and the endpoint was lifespan. Supplement trials used cardiovascular events as endpoints, and the index in them was not the target but, at best, a measured parameter. The claim "raise your index to eight per cent and you will live longer" is not supported by a trial of that design — neither a positive one nor a negative one; there simply is not one.

There is no international consensus naming the index a treatment target. The zones were proposed by the method's authors and are widely used in research, but that is not the same as a target level in a clinical guideline — the way it works, for instance, for LDL cholesterol, where targets are written down by risk category.

There is no basis for reading a single measurement as a characteristic of a person. One number without a method, without a matrix and without a second measurement months later is a point, not a series.

What to do with the number

The practical frame that follows from all of the above is short.

1. Read the header of the report, not just the figure: what was measured (red cells, whole blood, plasma) and what went into the sum (EPA + DHA, or something else).

2. Record the laboratory and the method. The next measurement goes to the same place by the same method, or there will be nothing to compare.

3. Do not compare against other people's numbers from social media or marketing materials: they were almost always produced by a different method.

4. Discuss a low value with a doctor — together with the rest of the picture rather than in isolation, especially if you take medication affecting coagulation.

5. Repeat no sooner than three to four months after any change in diet or intake — before that the marker has not reached a new steady state.

The same gap between observation and intervention shapes other longevity markers — VO2max and lipid measures among them: the link with outcomes comes from cohorts, while the question "what changes if you move it" is settled only by trials.

In the Lonevi record, if this marker has been measured for you, it sits alongside the others and is visible over time — and time is the point here: one value answers "where am I now", a series of three answers "is this moving at all".

This material is informational and does not replace a consultation with a doctor. Decisions about taking any medication or supplement, about changing your diet, and about which tests you need are made together with your treating physician.

References

• Harris W.S., von Schacky C. (2004). The Omega-3 Index: a new risk factor for death from coronary heart disease? Preventive Medicine, 39(1), 212–220. PMID 15208005.

• Harris W.S. et al. (2021). Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies. Nature Communications, 12, 2329. PMID 33888689.

• Stark K.D. et al. (2016). Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. Progress in Lipid Research, 63, 132–152. PMID 27216485.

• Flock M.R. et al. (2013). Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial. Journal of the American Heart Association, 2(6), e000513. PMID 24252845.

• Burdge G.C., Calder P.C. (2005). Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reproduction Nutrition Development, 45(5), 581–597. PMID 16188209.

• Davidson M.H. et al. (2012). A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters. Journal of Clinical Lipidology, 6(6), 573–584. PMID 23312053.

• Manson J.E. et al. (2019). Marine n-3 fatty acids and prevention of cardiovascular disease and cancer (VITAL). New England Journal of Medicine, 380, 23–32. PMID 30415637.

• Bhatt D.L. et al. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). New England Journal of Medicine, 380, 11–22. PMID 30415628.

• Nicholls S.J. et al. (2020). Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk (STRENGTH). JAMA, 324(22), 2268–2280. PMID 33190147.

• Gencer B. et al. (2021). Effect of long-term marine omega-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation, 144(25), 1981–1990. PMID 34612056.